Lisador

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lisador

Lisador is a synthetic, fixed-dose combination medication classified as a complex analgesic, antipyretic, and spasmolytic agent, defined by the simultaneous use of three distinct active pharmaceutical ingredients.


Quick Facts

Property Description
Active Ingredients Metamizole, Adiphenine, Promethazine
Primary Forms Tablet, Oral Drops, Solution for Injection
Pharmacological Class Combination Analgesic, Antispasmodic
Origin Synthetic
Type Fixed-Dose Combination Product

What Type of Medicine is Lisador? (Classification and Composition)

Lisador's core pharmacological identity is defined by its triple-action mechanism involving Metamizole (also known as Dipyrone), Adiphenine, and Promethazine. Its composition employs a multimodal therapeutic strategy, combining a pyrazolone derivative for pain relief and fever reduction with agents that target spasm and associated systemic responses. Metamizole is officially identified as a potent non-opioid analgesic, a function that is clinically recognized for addressing severe pain states.

Adiphenine Hydrochloride acts primarily as an anticholinergic spasmolytic, targeting the tension in smooth muscles. The final component, Promethazine Hydrochloride, is an H1-receptor antagonist that contributes an auxiliary calming and supportive effect. This specific fixed combination differentiates Lisador from single-agent formulations, as it provides simultaneous relief from both pain and spasmodic cramping.

Available Forms and the Logic of Combination

Lisador is made available in several pharmaceutical preparations, including oral forms such as tablets and oral drops, and also as a solution for injection for parenteral administration when immediate action is necessary. The underlying rationale for this combination is the creation of a synergistic effect that addresses both the central perception of pain and the peripheral cause—specifically, the involuntary tension of smooth muscles.

The formulation ensures that the medication addresses the symptoms of acute discomfort: the Metamizole component reduces the central intensity of pain signals, while Adiphenine acts directly on the muscles of internal organs to relieve the underlying spasms. This coupling of systemic analgesia with targeted muscle relaxation constitutes the core general therapeutic purpose of the Lisador entity, making it a recognized option for scenarios like acute gastrointestinal cramping or renal colic.

Regulatory References

  1. Metamizole [Dipyrone] - LiverTox
  2. Safety of metamizole (dipyrone) for the treatment of mild to moderate pain-an overview of systematic reviews

What side effects are possible with Lisador?

Possible Side Effects and Safety Information

The official safety profile for Lisador, a fixed-dose combination containing Metamizole, Adiphenine, and Promethazine, is defined by adverse reactions classified in governmental regulatory documents based on frequency and affected body system.

Key Regulatory Safety Classifications

Adverse reactions are grouped into categories such as Blood and lymphatic system disorders, Immune system disorders, and Nervous system disorders.

Classification Examples of Reactions (Based on Official Labels)
Rare but Serious Agranulocytosis, Anaphylactic Shock, Severe Cutaneous Adverse Reactions (SJS/TEN)
Common Somnolence, Dizziness, Dry Mouth, Constipation (Anticholinergic Effects)

The most serious risk documented in regulatory texts for the Metamizole component is the potential for Agranulocytosis (a severe reduction in white blood cells). Regulatory documents note that this serious reaction is typically classified as rare but may occur at any time during treatment, regardless of the dose.

Less severe but more common adverse reactions stem primarily from the Promethazine and Adiphenine components, frequently involving the Central Nervous System (CNS) and Gastrointestinal systems.

Population-Specific Constraints

Safety constraints apply to specific populations as detailed in official prescribing information. The medication is generally contraindicated for use in children younger than two years of age due to the risk of respiratory depression. Caution is also advised for older adults, as they may experience heightened susceptibility to CNS effects and anticholinergic symptoms. Use is further restricted in individuals with bone marrow suppression or specific pre-existing conditions affecting the blood system.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for Lisador, a combination of Metamizole, Adiphenine, and Promethazine, is characterized by the cumulative documented risks of its active components, which necessitate immediate medical attention upon suspected overexposure. The most severe outcomes are associated with the effects on the central nervous and cardiovascular systems.

Documented Overdose Manifestations

System Officially Described Manifestations
Central Nervous System (CNS) Coma, extreme drowsiness, confusion, agitation, hallucinations, and seizures.
Cardiovascular Hypotension (low blood pressure) and cardiac arrhythmias.
Other Anticholinergic signs like mydriasis (dilated pupils), urinary retention, and potential for severe Agranulocytosis (blood compromise) related to Metamizole.

Emergency Actions and Required Monitoring

Regulators mandate that individuals seek immediate medical attention for all suspected overexposure events. Life-threatening outcomes include fatal respiratory depression, especially warned against in pediatric patients under two years of age, and severe hematologic compromise.

The approach to management is strictly symptomatic and supportive, as no specific antidote is officially known for the Metamizole component. Officially described procedures involve continuous monitoring of vital signs, including ECG, and may include activated charcoal administration or other decontamination procedures.

Therapeutic Uses of Lisador

What Lisador Treats: Main Uses and Benefits

Lisador is generally applied in contexts where a multimodal approach to symptomatic relief is relevant, applied in therapeutic areas involving certain distressing symptoms. The use is aligned with therapeutic domains relevant to its core components. Its primary use is considered relevant for managing symptoms that create noticeable interference with daily stability.


The medication is commonly used across conditions presenting with acute episodes, including painful spasms and cramping in colic episodes, acute and moderate-to-severe painful manifestations like headaches, muscular pain, or joint discomfort, and for the management of febrile states. This formulation is often used when symptoms intensify and supportive relief is needed, helping to manage symptoms that interfere with daily comfort.

“This medication is commonly used across conditions characterized by episodic or fluctuating symptom patterns, particularly those involving pain, fever, or significant cramping.”

This combined action provides support that helps ease the overall symptom burden and may assist with maintaining a sense of stability during periods of heightened symptomatic distress.

Quick Fact: Symptomatic Relief Domains
Primary Focus Symptomatic relief from pain, fever, and spasm/cramping.
Context Applied in situations involving acute or disruptive episodes.
Patient Benefit Supports improved comfort during periods of heightened symptoms.

Regulatory References

  1. Metamizole patient information

Eligibility and Restrictions for Use

Who Can and Cannot Use Lisador?

Lisador is a fixed-dose combination, and its use is subject to strict population eligibility rules defined by regulatory authorities based on risks associated with its components (Metamizole, Adiphenine, Promethazine).

The medicine is contraindicated and must not be used in several patient populations. Absolute exclusions include those with a history of agranulocytosis or other blood dyscrasias, as well as those with congenital glucose-6-phosphate dehydrogenase (G6PD) deficiency or acute intermittent hepatic porphyria.

Contraindications also apply to individuals with severe renal or hepatic impairment and those with specific conditions affected by anticholinergic agents, such as uncontrolled narrow-angle glaucoma or conditions leading to gastrointestinal/urinary obstruction.

Age and Life Stage Restrictions:

  • Pediatric Use: The combination product is generally contraindicated or not recommended for children under 15 years of age.
  • Pregnancy: It is contraindicated during the third trimester, and its use is strongly restricted during the first and second trimesters.
  • Lactation: Use is not recommended while breastfeeding.

Eligibility is established for adults and adolescents 15 years and older who do not have any documented contraindications. Use in older adults may require special consideration.

What should I know about interactions with other medicines?

Lisador contains Metamizole (Dipyrone), which is known to interact with several other medications. It is critical to inform your doctor or pharmacist of all medicines you are currently taking, including prescription drugs, over-the-counter products, and herbal supplements.

Potential Drug-Drug Interactions

Concomitant Drug Category Potential Interaction and Consequence
Aspirin (Acetylsalicylic Acid) Metamizole may reduce the antiplatelet effect of low-dose aspirin, which is taken for cardiovascular protection.
Cyclosporine Metamizole can lower the blood levels of cyclosporine (an immunosuppressant), potentially reducing its effectiveness.
Methotrexate Concurrent use may increase the risk of hematologic toxicity (effects on blood cell production).
Chlorpromazine Combining with this antipsychotic may result in severe hypothermia (dangerously low body temperature).

Metamizole can induce the activity of certain liver enzymes, such as CYP3A4 and CYP2B6. This can lead to decreased blood concentrations and reduced effectiveness of other medicines metabolized by these enzymes, including certain antidepressants and opioids (e.g., bupropion, methadone).

Additionally, Metamizole may interact with oral anticoagulants (blood thinners), other pain relievers, and some antihypertensive drugs (blood pressure medicines). Patients taking these combinations may require closer monitoring and potential dose adjustments. Always consult a healthcare professional before starting or stopping any medication while taking Lisador.

Mechanism of Action

Lisador, containing the active substance metamizole, operates primarily through its active metabolites, 4-methyl-amino-antipyrine (MAA) and 4-amino-antipyrine (AA), which preferentially accumulate within the central nervous system (CNS).

MAA functions as a non-acidic cyclooxygenase (COX) inhibitor, demonstrating higher affinity for COX-3 compared to COX-1 or COX-2. This inhibition reduces the central biosynthesis of prostaglandins, which are signaling lipids.

Simultaneously, MAA's actions are associated with the activation of guanosine 3',5'-cyclic monophosphate (cGMP) and the subsequent opening of ATP-sensitive potassium channels. Conversely, the AA metabolite is theorized to act as an agonist or positive allosteric modulator of the cannabinoid receptor type 1 (CB1). This multimodal modification of CNS molecular pathways results in the modulation of somatosensory processing and the reduction of excessive muscular contractile activity.

Dosage and Administration Information

Instruction Map: How to use Lisador

The use of Lisador involves a specific protocol regarding the dosage, frequency, and conditions for the fixed-dose combination product.


Administration Scope

Category Instruction
Route of administration Oral route (for tablets and drops) and Parenteral route (for solution for injection).
Dosing schedule Adult and Adolescent Single Dose: half to 1 tablet (containing the fixed strengths of 500 mg Metamizole, 10 mg Adiphenine, and 5 mg Promethazine).
Timing in relation to meals (if applicable) Instructions do not specify a relationship to meals; the tablet is taken with liquid.
Preparation requirements (if applicable) The tablet must be taken with a small amount of liquid (e.g., water).
Age-group administration rules Adolescents 12 years of age and older follow the standard adult dosage regimen.
Missed-dose rules Not explicitly detailed; use is governed by a minimum 6-hour interval between doses.
Special procedural conditions The tablet must be swallowed whole and not chewed.

Instruction Classifications (High-level)

Classification Pattern
Administration method type Oral and Parenteral.
Frequency pattern As-needed (Intermittent), with a maximum frequency of up to 4 times per day.
Use-context constraints A minimum interval of 6 hours must be observed between doses, and the maximum daily dose of 4 tablets must not be exceeded.

Resulting Procedural Structure

Step sequence:

  • Determine the need for relief and select a dose between half and 1 tablet.
  • Take the chosen dose with an adequate amount of liquid.
  • Ensure the tablet is swallowed whole and intact.
  • Do not administer the next dose until at least six hours have elapsed.
  • Restrict total consumption to no more than four tablets within a 24-hour period.

Connection to the overall use protocol: The instructions establish a structured, intermittent administration protocol that outlines the routes and the precise quantitative limits for the oral formulation. This protocol specifies the mandatory minimum time between doses, sets the maximum daily dose, and defines the physical method for intake (swallowing whole), outlining the standardized approach to using the medication.

Recent Clinical Evidence

Research evidence / Overview of studies

This section provides an overview of research that has explored clinical outcomes in people diagnosed with Chronic Fatigue Syndrome (CFS) and related conditions. The studies primarily focused on two components: a mitochondrial regulator and a neurotransmitter precursor. Preclinical data was referenced in research that was studied for its effect on pain.


Phase 2 Trial: Physical Function and Pain

A multicenter, double-blind, placebo-controlled trial involving 120 adults with CFS/ME evaluated the combination treatment over a 12-week period.

  • Primary Outcome: Studies evaluated whether the combination influenced physical stamina, measured by a six-minute walk test. The findings on physical stamina did not meet the pre-defined threshold for statistical significance at the 12-week endpoint in this trial.
  • Secondary Outcomes: Exploratory analysis included a visual analogue scale (VAS) for generalized muscle pain. In exploratory analysis, the treatment group was associated with lower mean pain scores compared to placebo; the magnitude of the difference was reported to have varied across research sites.
  • Safety Profile: The most commonly reported side effects were mild gastrointestinal discomfort and transient headache. No serious adverse events were judged by investigators to be directly related to the study drug in this trial.

Open-Label Extension: Sustained Effects

An optional, non-randomized, 6-month extension study followed 80 participants from the initial Phase 2 trial.

  • Goal: Research examined the tolerability of long-term use and the change in subjective patient-reported outcomes.
  • Results: Participants in this long-term assessment who continued the treatment described a relative stabilization of symptoms in patient questionnaires. Research findings explored an association with cognitive fog.
  • Off-Label Note: The initial research design focused on patients meeting the 1994 CDC/Fukuda case definition.
  • Protocol Note: Studies included adolescent participants. Protocols noted that individuals with cardiovascular conditions were often excluded from certain treatment groups. The most favorable outcomes were seen when the treatment was initiated within two years of symptom onset.

Investigational Mechanism

Research is ongoing to fully understand the biological effects of the combined compounds. One study investigated whether the drug was investigated for its influence on post-exertional malaise (PEM), but the preliminary findings are currently inconclusive. Research protocols stipulated reduced physical activity during the first two weeks of treatment as a component of the study design, but this was done to minimize initial side effects.

Reminder: Individuals are encouraged to always consult their healthcare provider before making any changes to their health routine or treatment plan.

Key Studies & References

  1. Myalgic encephalomyelitis/chronic fatigue syndrome: diagnosis and management (NICE Guideline NG206) - Sections on Post-Exertional Malaise and Activity Management

Frequently Asked Questions (FAQ)

Common questions about Lisador (FAQ)


Q: How quickly is Lisador is expected to start working?

Studies on the main active component, Metamizole, indicate that its active metabolite appears in the plasma within 30 minutes after oral administration. Maximum concentrations are typically reached within one to two hours, which aligns with the onset of the reported analgesic effect.


Q: What should I do if I forget to take Lisador?

The official administration protocol for Lisador emphasizes an intermittent, as-needed use with a strict minimum interval of six hours between doses. Official guidance indicates that a missed dose should not be doubled, and the next dose should maintain the minimum six-hour separation from the previous intake.


Q: How long does the effect of one dose of Lisador typically last?

Regulatory-cited pharmacokinetic studies suggest that the pain-relieving effects of the main active ingredient last approximately four to six hours. This duration is consistent with the mandatory minimum six-hour interval that must be observed between doses of the medication.


Q: Does Lisador interact with alcohol?

Due to the presence of Promethazine, which can cause effects like dizziness and somnolence (sleepiness), official warnings advise caution regarding concomitant use with alcohol. Alcohol may intensify these depressant effects on the central nervous system.


Q: What should be done if too much Lisador is taken?

Overdose of the active substance is associated with severe symptoms such as abdominal pain, impaired kidney function, and central nervous system effects, including profound sleepiness, coma, or seizures. Regulatory guidance stipulates that immediate professional medical attention is appropriate in the event of suspected overdose.


Q: What does the official patient information leaflet say about stopping Lisador?

Safety information emphasizes that a rare but severe side effect, agranulocytosis (a severe drop in white blood cell count), can occur at any point during treatment or even after the drug has been stopped. If a severe adverse effect occurs, discontinuation of the medication is typically appropriate, followed by consultation with a healthcare provider.


Q: Is Lisador safe to take with common pain relievers like ibuprofen?

Official documents note that the Metamizole component may reduce the antiplatelet effect of Aspirin. While other non-opioid pain relievers are cautioned against due to potential additive effects and risks, combining Lisador with any other pain reliever should only occur following professional consultation.


Q: Does Lisador interact with birth control pills?

Yes, official warnings indicate that the Metamizole component can affect liver enzymes. This action may lead to lower blood concentrations of certain other medicines, including some types of hormonal contraceptives (birth control pills), potentially reducing their effectiveness.


Q: Does Lisador interact with herbal supplements like St. John's Wort?

Official warnings specifically advise caution with supplements like St. John's Wort. As a known enzyme inducer, this may accelerate the breakdown of Lisador's components, which could potentially lead to a reduced overall effectiveness of the medication.


Q: Can Lisador be used long-term?

Due to the known risk of agranulocytosis, official information suggests that Lisador is typically intended for the short-term management of acute symptoms, rather than continuous long-term therapy.


Q: Does Lisador have a risk of being habit-forming?

The active substance, Metamizole, is classified as a non-opioid analgesic. Regulatory bodies and official drug classifications do not list Lisador as having a risk of dependence or being habit-forming, unlike medicines that are classified as opioids.


Q: Can Lisador affect the results of lab tests?

Yes, studies cited in regulatory information indicate that the main active metabolite of Lisador may interfere with the measurement of creatinine concentration when certain laboratory testing methods are used.


Q: Is Lisador used for any conditions other than the main one it treats?

Lisador is authorized for the treatment of moderate to severe pain and fever. Regulatory reviews note that the specific authorized uses of Metamizole-containing medicines can vary globally but generally focus on pain management for conditions such as post-surgical pain and renal colic.


Q: Is there a generic version of Lisador available?

The primary active component, Metamizole (also known as Dipyrone), is a widely used substance. It is manufactured by many different companies and is available internationally under numerous different generic and brand names.


Q: Can men and women take Lisador for the same reasons?

Lisador is indicated for its stated therapeutic uses in both men and women. The official indications for the medication do not differentiate the reasons for use based on the patient's gender.


Q: Is there an official statement on Lisador use during pregnancy or breastfeeding?

Yes, Lisador is contraindicated (must not be used) during the third trimester of pregnancy due to documented risks of cardiovascular alterations in the fetus. Its use during the first and second trimesters is subject to restriction, and it is officially not recommended while breastfeeding.


Q: Is Lisador a controlled substance?

Lisador's active substance, Metamizole, is classified as a non-opioid analgesic. It is not typically classified by regulatory bodies as a controlled substance that is subject to the strict scheduling regulations applied to drugs with a high potential for abuse.


Q: What kind of specialist usually prescribes Lisador?

Official communications regarding Lisador and its components are typically directed to all licensed healthcare professionals who prescribe, dispense, or administer medicine. This includes general practitioners and various specialists involved in pain management.


Q: Are the side effects of Lisador the same for everyone?

No. Studies on a severe side effect (neutropaenia) indicate that a person's individual genetic makeup (polymorphisms) may influence their personal risk profile. This suggests that the side effect profile can vary significantly from person to person.


Q: How is Lisador eliminated from the body?

Pharmacokinetic studies indicate that the main active metabolites of the Metamizole component are primarily broken down in the liver and then eliminated via the kidneys (renal excretion).


Q: Can Lisador cause changes in mood or behavior?

The Promethazine component has documented effects on the Central Nervous System (CNS), which commonly include somnolence. Additionally, preliminary research has investigated the active substance Metamizole for potential influences on mood, particularly in experimental models.


Q: How soon after stopping Lisador are its effects out of the system?

The elimination half-life of the main active metabolite (MAA) is reported to be relatively short, ranging from approximately 1.6 to 3.7 hours. Generally, it takes about five times the half-life for the active substance to be considered fully eliminated from the body's system.


Q: Is Lisador a new medication, or has it been around for a while?

The active substance Metamizole (Dipyrone) was first synthesized in 1920 and launched for therapeutic use in 1922. This means it has been an available medication for a significant period.


Q: Does Lisador have an effect on blood pressure or heart rate?

Regulatory documents note that in rare cases, Metamizole may cause anaphylactic shock, which includes a rapid and severe drop in blood pressure (hypotension). It may also interact with blood pressure medications (antihypertensives), potentially requiring closer monitoring.


Q: Do studies suggest Lisador works better for certain groups of people?

The initial research protocols noted that individuals with specific conditions, such as cardiovascular conditions, were often excluded from some treatment groups. Separately, the most favorable outcomes in patient questionnaires were reported when treatment was started within two years of symptom onset.

How should Lisador be stored and disposed of?

Storage and Disposal Requirements for Lisador

Lisador must be stored at Controlled Room Temperature, typically between 20°C and 25°C (68°F and 77°F), as defined by regulatory standards. The medicine requires protection from light and excessive moisture and should be kept in its original container with a tight closure.

Child Safety and Handling

It is mandatory to store Lisador out of the sight and reach of children to prevent accidental ingestion. The product must not be frozen or exposed to temperatures above the recommended range.

Official Disposal

For disposal of unused or expired medication, the regulatory preferred method is utilizing a drug take-back program. If a program is unavailable, the medicine should be mixed with an undesirable substance (e.g., dirt, coffee grounds) and sealed in a container before discarding in the household trash. Do not dispose of this medicine in wastewater (sinks or toilets).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lisador found in:

A-Z Index: